HarbourVest Partners LLC decreased its position in shares of MyoKardia, Inc. (NASDAQ:MYOK) by 53.8% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 44,145 shares of the biotechnology company’s stock after selling 51,374 shares during the quarter. MyoKardia comprises approximately 0.2% of HarbourVest Partners LLC’s investment portfolio, making the stock its 15th largest position. HarbourVest Partners LLC owned approximately 0.14% of MyoKardia worth $578,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Nationwide Fund Advisors raised its holdings in MyoKardia by 36.3% during the 2nd quarter. Nationwide Fund Advisors now owns 9,729 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 2,591 shares during the last quarter. Highbridge Capital Management LLC bought a new position in MyoKardia during the 1st quarter worth approximately $136,000. Alliancebernstein L.P. bought a new position in MyoKardia during the 2nd quarter worth approximately $148,000. State of Wisconsin Investment Board bought a new position in MyoKardia during the 2nd quarter worth approximately $157,000. Finally, Rhumbline Advisers raised its holdings in MyoKardia by 45.4% during the 2nd quarter. Rhumbline Advisers now owns 18,489 shares of the biotechnology company’s stock worth $242,000 after purchasing an additional 5,773 shares during the last quarter. Hedge funds and other institutional investors own 42.94% of the company’s stock.

In other MyoKardia news, Director Wendy L. Yarno bought 1,408 shares of the firm’s stock in a transaction that occurred on Monday, August 14th. The stock was bought at an average price of $35.50 per share, for a total transaction of $49,984.00. Following the completion of the acquisition, the director now directly owns 1,408 shares in the company, valued at $49,984. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Anastasios Gianakakos sold 4,300 shares of the company’s stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $16.62, for a total value of $71,466.00. Following the transaction, the chief executive officer now owns 512,463 shares of the company’s stock, valued at approximately $8,517,135.06. The disclosure for this sale can be found here. Insiders sold 1,706,888 shares of company stock valued at $71,162,510 in the last quarter. Corporate insiders own 46.10% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.watchlistnews.com/harbourvest-partners-llc-has-578000-holdings-in-myokardia-inc-myok/1599087.html.

MyoKardia, Inc. (MYOK) traded up 0.71% on Friday, reaching $42.85. 532,578 shares of the company’s stock traded hands. The firm’s market cap is $1.35 billion. The firm’s 50-day moving average is $45.18 and its 200 day moving average is $45.18. MyoKardia, Inc. has a 12 month low of $10.55 and a 12 month high of $49.55.

MyoKardia (NASDAQ:MYOK) last announced its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.41) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.04). MyoKardia had a negative net margin of 44.65% and a negative return on equity of 16.35%. The company had revenue of $5.60 million during the quarter, compared to the consensus estimate of $6.73 million. During the same quarter in the previous year, the firm posted ($0.37) EPS. The business’s revenue for the quarter was up 60.0% compared to the same quarter last year. Equities analysts predict that MyoKardia, Inc. will post ($1.63) EPS for the current year.

Several research analysts have issued reports on the stock. BMO Capital Markets restated a “buy” rating and set a $45.00 price target (up previously from $32.00) on shares of MyoKardia in a report on Tuesday, August 8th. ValuEngine upgraded shares of MyoKardia from a “sell” rating to a “hold” rating in a report on Monday, August 7th. TheStreet upgraded shares of MyoKardia from a “d+” rating to a “c” rating in a report on Thursday, July 6th. Wedbush restated an “outperform” rating and set a $51.00 price target on shares of MyoKardia in a report on Wednesday, September 20th. Finally, Credit Suisse Group restated an “outperform” rating and set a $55.00 price target (up previously from $45.00) on shares of MyoKardia in a report on Tuesday, September 19th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $48.33.

MyoKardia Company Profile

MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.

Want to see what other hedge funds are holding MYOK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MyoKardia, Inc. (NASDAQ:MYOK).

Institutional Ownership by Quarter for MyoKardia (NASDAQ:MYOK)

Receive News & Ratings for MyoKardia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyoKardia Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.